Icodextrin metabolites in peritoneal dialysis

Peritoneal Dialysis International

Volumn 29, Issue 4, 2009, Pages 370-376

  García López, Elvia ^a   Lindholm, Bengt ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLASE; GLUCOSE POLYMER; ICODEXTRIN;

BLOOD OSMOLARITY; CAPILLARY ENDOTHELIUM; ENZYME BLOOD LEVEL; GLUCOSE ABSORPTION; GLUCOSE METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROLYSIS; METABOLITE; PATIENT SAFETY; PERITONEAL DIALYSIS; PERITONEUM; PRIORITY JOURNAL; REVIEW; ULTRAFILTRATION; URINARY EXCRETION;

EID: 70349512452     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080902900402     Document Type: Review

References (52)

1. Holmes CJ. Glucotoxicity in peritoneal dialysis - solutions for the solution! Adv Chronic Kidney Dis 2007; 14:269-78.
2. Heimbürger O. Peritoneal physiology. In: Pereira BJG, Sayegh MH, Blake P, eds. Chronic Kidney Disease, Dialysis, & Transplantation: Companion to Brenner & Rector's the Kidney. 2nd ed. Philadelphia: Elsevier Saunders; 2005: 491-513.
3. Krediet RT. Osmotic agents in automated peritoneal dialysis solutions. Contrib Nephrol 1999; 129:177-86.
4. Heimburger O, Lindholm B. New solutions for peritoneal dialysis. In: Falkenhagen D, Klinkmann H, Piskin E, eds. Blood-Material Interaction. A Basic Guide from Polymer Science to Clinical Application. Glasgow: International Faculty for Artificial Organs; 1998: 129-36.
5. Rippe B, Levin L. Computer simulations of ultrafiltration profiles for an icodextrin-based peritoneal fluid in CAPD. Kidney Int 2000; 57:2546-56.
6. Ho-dac-Pannekeet MM, Schouten N, Langendijk MJ, Hiralall JK, de Waart DR, Struijk DG, et al. Peritoneal transport characteristics with glucose polymer based dialysate. Kidney Int 1996; 50:979-86.
7. Pecoits-Filho R, Mujais S, Lindholm B. Future of icodextrin as an osmotic agent in peritoneal dialysis. Kidney Int Suppl 2002; 81:S80-7.
8. Davies SJ, Brown EA, Frandsen NE, Rodrigues AS, Rodriguez-Carmona A, Vychytil A, et al. Longitudinal membrane function in functionally anuric patients treated with APD: data from EAPOS on the effects of glucose and icodextrin prescription. Kidney Int 2005; 67:1609-15.
9. Alsop RM. History, chemical and pharmaceutical development of icodextrin. Perit Dial Int 1994; 14(Suppl 2): S5-12.
10. Moberly JB, Mujais S, Gehr T, Hamburger R, Sprague S, Kucharski A, et al. Pharmacokinetics of icodextrin in peritoneal dialysis patients. Kidney Int Suppl 2002; 81: S23-33.
11. Mujais S, Vonesh E. Profiling of peritoneal ultrafiltration. Kidney Int Suppl 2002; 81:S17-22.
12. Finkelstein F, Healy H, Abu-Alfa A, Ahmad S, Brown F, Gehr T, et al. Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration. J Am Soc Nephrol 2005; 16:546-54.
13. Peers E, Gokal R. Icodextrin: overview of clinical experience. Perit Dial Int 1997; 17:22-6.
14. Gokal R. Newer peritoneal dialysis solutions. Adv Ren Replace Ther 2000; 7:302-9.
15. Shockley TR, Martis L, Tranaeus AP. New solutions for peritoneal dialysis in adult and pediatric patients. Perit Dial Int 1999; 19(Suppl 2):S429-34.
16. Krediet RT. The physiology of peritoneal solute transport and ultrafiltration. In: Gokal R, Khanna R, Krediet RT, Nolph KD, eds. Textbook of Peritoneal Dialysis. 2nd ed. Amsterdam: Kluwer Academic Publishers; 2000: 135-72.
17. Wang T, Lindholm B. Peritoneal dialysis solutions. Perit Dial Int 2001; 21(Suppl 3):S89-95.
18. Krishnan M, Tam P, Wu G, Breborowicz A, Oreopoulos DG. Glucose degradation products (GDP's) and peritoneal changes in patients on chronic peritoneal dialysis: will new dialysis solutions prevent these changes? Int Urol Nephrol 2005; 37:409-18.
19. Frampton J, Plosker G. Icodextrin: a review of its use in peritoneal dialysis. Drugs 2003; 63:2079-105.
20. Davies DS. Kinetics of icodextrin. Perit Dial Int 1994; 14(Suppl 2):S45-50.
21. Asghar RB, Diskin AM, Spanel P, Smith D, Davies SJ. Influence of convection on the diffusive transport and sieving of water and small solutes across the peritoneal membrane. J Am Soc Nephrol 2005; 16:437-43.
22. Mistry CD, Gokal R, Peers E. A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis. Kidney Int 1994; 46:496-503.
23. Mistry CD, Mallick NP, Gokal R. Ultrafiltration with an isosmotic solution during long peritoneal dialysis exchanges. Lancet 1987; 2:178-82.
24. Garcia-Lopez E, Anderstam B, Heimburger O, Amici G, Werynski A, Lindholm B. Determination of high and low molecular weight molecules of icodextrin in plasma and dialysate, using gel filtration chromatography, in peritoneal dialysis patients. Perit Dial Int 2005; 25:181-91.
25. Wang R, Moberly JB, Martis L, Shockley TR, Mongoven JW, Patel H, et al. A rapid assay for icodextrin determination in plasma and dialysate. Adv Perit Dial 2002; 18:91-5.
26. Garcia-Lopez E, Pawlaczyk K, Anderstam B, Qureshi AR, Kuzlan-Pawlaczyk M, Heimburger O, et al. Icodextrin metabolism and alpha-amylase activity in nonuremic rats undergoing chronic peritoneal dialysis. Perit Dial Int 2007; 27:415-23.
27. Mistry CD, Gokal R. Icodextrin in peritoneal dialysis: early development and clinical use. Perit Dial Int 1994; 14(Suppl 2):S13-21.
28. Burke RA, Hvizd MG, Shockley TR. Direct determination of polyglucose metabolites in plasma using anion-exchange chromatography with pulsed amperometric detection. J Chromatogr B Biomed Sci Appl 1997; 693:353-7.
29. Anderstam B, Garcia-Lopez E, Heimburger O, Lindholm B. Determination of alpha-amylase activity in serum and dialysate from patients using icodextrin-based peritoneal dialysis fluid. Perit Dial Int 2003; 23:146-50.
30. Davies SJ, Garcia-Lopez E, Woodrow G, Donovan K, Plum J, Williams P, et al. Longitudinal relationships between fluid status, inflammation, urine volume and plasma metabolites of icodextrin in patients randomized to glucose or icodextrin for the long exchange. Nephrol Dial Transplant 2008; 23:2982-8.
31. Garcia-Lopez E, Werynski A, Heimburger O, Filho JC, Lindholm B, Anderstam B. Rate of synthetic oligosaccharide degradation as a novel measure of amylase activity in peritoneal dialysis patients. Perit Dial Int 2008; 28: 296-304.
32. Plum J, Gentile S, Verger C, Brunkhorst R, Bahner U, Faller B, et al. Efficacy and safety of a 7.5% icodextrin peritoneal dialysis solution in patients treated with automated peritoneal dialysis. Am J Kidney Dis 2002; 39:862-71.
33. Wolfson M, Piraino B, Hamburger RJ, Morton AR. A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis. Am J Kidney Dis 2002; 40:1055-65.
34. Ota K, Akiba T, Nakao T, Nakayama M, Maeba T, Park MS, et al. Peritoneal ultrafiltration and serum icodextrin concentration during dialysis with 7.5% icodextrin solution in Japanese patients. Perit Dial Int 2003; 23:356-61.
35. Rodriguez-Carmona A, Perez Fontan M, Garcia Lopez E, Garcia Falcon T, Diaz Cambre H. Use of icodextrin during nocturnal automated peritoneal dialysis allows sustained ultrafiltration while reducing the peritoneal glucose load: a randomized crossover study. Perit Dial Int 2007; 27: 260-6.
36. Posthuma N, ter Wee PM, Donker AJ, Oe PL, Peers EM, Verbrugh HA. Assessment of the effectiveness, safety, and biocompatibility of icodextrin in automated peritoneal dialysis. The Dextrin in APD in Amsterdam (DIANA) Group. Perit Dial Int 2000; 20(Suppl 2):S106-13.
37. de Waart DR, Zweers MM, Struijk DG, Krediet RT. Icodextrin degradation products in spent dialysate of CAPD patients and the rat, and its relation with dialysate osmolality. Perit Dial Int 2001; 21:269-74.
38. Flessner MF, Lofthouse J. Of mice and men: species and age differences in dialysis with icodextrin [Abstract]. J Am Soc Nephrol 1999; 10:226A.
39. de Boer AW, Schroeder CH, van Vliet R, Willems JL, Monnens LA. Clinical experience with icodextrin in children: ultrafiltration profiles and metabolism. Pediatr Nephrol 2000; 15:21-4.
40. Gobin J, Fernando S, Santacroce S, Finkelstein FO. The utility of two daytime icodextrin exchanges to reduce dextrose exposure in automated peritoneal dialysis patients: a pilot study of nine patients. Blood Purif 2008; 26: 279-83.
41. García-López E. Icodextrin metabolism in peritoneal dialysis: clinical and experimental studies [Thesis]. ISBN 978-91-7357-352-8. Stockholm: Karolinska Institutet; 2007.
42. Grzegorzewska AE, Antczak-Jedrzejczak D, Mariak I. Polyglucose dialysis solution influences serum activity of amylase and of lipase differently. Adv Perit Dial 2000; 16: 113-18.
43. Mistry CD, Gokal R. Single daily overnight (12-h dwell) use of 7.5% glucose polymer (Mw 18700; Mn 7300) +0.35% glucose solution: a 3-month study. Nephrol Dial Transplant 1993; 8:443-7.
44. Schoenicke G, Grabensee B, Plum J. Dialysis with icodextrin interferes with measurement of serum alpha-amylase activity. Nephrol Dial Transplant 2002; 17:1988-92.
45. Wang R, Leesch V, Turner P, Moberly JB, Martis L. Kinetic analysis of icodextrin interference with serum amylase assays. Adv Perit Dial 2002; 18:96-9.
46. Posthuma N, ter Wee PM, Donker AJ, Oe PL, van Dorp W, Peers EM, et al. Serum disaccharides and osmolality in CCPD patients using icodextrin or glucose as daytime dwell. Perit Dial Int 1997; 17:602-7.
47. Van Handel E. Trehalase and maltase in the serum of vertebrates. Comp Biochem Physiol 1968; 26:561-6.
48. Weser E, Sleisenger MH. Metabolism of circulating disaccharides in man and the rat. J Clin Invest 1967; 46: 499-505.
49. Young JM, Weser E. The metabolism of circulating maltose in man. J Clin Invest 1971; 50:986-91.
50. Gokal R, Moberly J, Lindholm B, Mujais S. Metabolic and laboratory effects of icodextrin. Kidney Int Suppl 2002; 81:S62-71.
51. Martikainen T, Teppo AM, Gronhagen-Riska C, Ekstrand A. Benefit of glucose-free dialysis solutions on glucose and lipid metabolism in peritoneal dialysis patients. Blood Purif 2005; 23:303-10.
52. Davies SJ, Woodrow G, Donovan K, Plum J, Williams P, Johansson AC, et al. Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial. J Am Soc Nephrol 2003; 14: 2338-44.